cyclic peptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-04-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
== Early life and education == Cameron was born in Champaign, Illinois. The oldest of three brothers, he grew up in the Chicago suburb, Westchester, and graduated in 1975 from Proviso West High School, Hillside, Illinois. Cameron graduated from Duke University (1979) with a B.S.E. in Biomedical Engineering. In May 1979 he joined Advanced Harvesting Systems, a start-up company focused on large-scale plant protein purification, as the first non-founding member of the company. He was married in August 1979 to Sally Jo Clark. Cameron started graduate school at the Massachusetts Institute of Technology in July 1981 and graduated with a Ph.D. in biochemical engineering in December 1986. His Ph.D. advisor was Charles L. Cooney. His Ph.D. thesis was titled “The Production of R-1,2-Propanediol by Clostridium thermosaccharolyticum.”
The insulin/IGF/relaxin family is a group of evolutionarily related proteins which possess a variety of hormonal activities. In humans, these proteins are divided into two subsets: 1) insulin and insulin-like growth factors 2) relaxin family peptides:
2-Oxoadipic acid, also known as α-ketoadipic acid, is an intermediate in the metabolism of lysine and tryptophan. The conjugate base and carboxylate is 2-oxoadipate or α-ketoadipate, which is the biochemically relevant form. Glutaric acid is naturally produced by chain extension of α-ketoglutarate to 2-oxoadipic acid.
Sources: en.wikipedia.org
The brain requires approximately 3.3 ml of oxygen per 100 g of brain tissue per minute. Initially, the body responds to lowered blood oxygen by redirecting blood to the brain and increasing cerebral blood flow. Blood flow may increase up to twice the normal flow but no more. If the increased blood flow is sufficient to supply the brain's oxygen needs then no symptoms will result. However, if blood flow cannot be increased or if doubled blood flow does not correct the problem, symptoms of cerebral hypoxia will begin to appear. Mild symptoms include difficulties with complex learning tasks and reductions in short-term memory. If oxygen deprivation continues, cognitive disturbances and decreased motor control will result. The skin may also appear bluish (cyanosis) and heart rate increases. Continued oxygen deprivation results in fainting, long-term loss of consciousness, coma, seizures, cessation of brain stem reflexes, and brain death. Objective measurements of the severity of cerebral hypoxia depend on the cause. Blood oxygen saturation may be used for hypoxic hypoxia, but is generally meaningless in other forms of hypoxia. In hypoxic hypoxia 95–100% saturation is considered normal; 91–94% is considered mild and 86–90% moderate. Anything below 86% is considered severe. Cerebral hypoxia refers to oxygen levels in brain tissue, not blood. Blood oxygenation will usually appear normal in cases of hypemic, ischemic, and histotoxic cerebral hypoxia.
National authorities could be justified in refusing to reimburse patients for medical services abroad if the health care received at home was without undue delay, and it followed "international medical science" on which treatments counted as normal and necessary. The Court requires that the individual circumstances of a patient justify waiting lists, and this is also true in the context of the UK's National Health Service. Aside from public services, another sensitive field of services are those classified as illegal. Josemans v Burgemeester van Maastricht held that the Netherlands' regulation of cannabis consumption, including the prohibitions by some municipalities on tourists (but not Dutch nationals) going to coffee shops, fell outside article 56 altogether. The Court of Justice reasoned that narcotic drugs were controlled in all member states, and so this differed from other cases where prostitution or other quasi-legal activity was subject to restriction. If an activity does fall within article 56, a restriction can be justified under article 52, or by overriding requirements developed by the Court of Justice. In Alpine Investments BV v Minister van Financiën a business that sold commodities futures (with Merrill Lynch and another banking firms) attempted to challenge a Dutch law that prohibiting cold calling customers. The Court of Justice held the Dutch prohibition pursued a legitimate aim to prevent "undesirable developments in securities trading" including protecting the consumer from aggressive sales tactics, thus maintaining confidence in the Dutch markets.
== Mentions in culture == In the 2009 film inspired by Edgar Allan Poe's "The Tell-Tale Heart", Tell-Tale, Eastlack is mentioned and referred to as Harry Erlich. The mention occurs in a scene where characters are in a museum, and a skeleton is referred to. The scene provides some genuine facts, such as how Eastlack's skeleton does not require any wiring or glue to be held together in the museum because the fused bones hold it all in one piece.
Sources: en.wikipedia.org
== Career == In 1953 he was elected to a Life Fellowship at King's, where he remained for the whole of his academic career, holding the positions of Financial Tutor (1956–1959), Director of Studies in Natural Sciences (1961–1981), Vice Provost (1981–1986) and Praelector (1989–1992), as well as co-editor of the College Register. In 1954 he was appointed as University Demonstrator in biochemistry, and in 1959 was promoted to University Lecturer. From 1964 to 1965, he worked at the Engelhardt Institute of Molecular Biology in Moscow as part of a UK-USSR exchange program. Dixon was an editor of The Biochemical Journal, and was Deputy Chairman of the Editorial Board from 1977 to 1982. He was secretary of the Nomenclature Committee of the International Union of Biochemistry from 1977 to 1982 and chairman from 1983 to 1988, and after his retirement remained an advisory member. Dixon's research in chemistry and biochemistry led to 136 published papers. His interests included the pH-dependence of enzyme-catalysed reactions, arsenic biochemistry, protein modification and other aspects of enzymology. His particular interest in applications of methods from organic chemistry to biochemistry led to a proposed treatment for Wilson's disease. In 1957 he married Heather Spittle with whom he had three children. After his death, a set of rooms in the Gibbs' Building in King's College was named the Hal Dixon Rooms in his memory.
21 July – Writing in the Sun on Sunday, Home Secretary Yvette Cooper announces that car washes and beauty salons will be targeted by immigration officials over the summer in a bid to crack down on businesses illegally hiring workers from overseas. Former Chancellor Jeremy Hunt, who was Health Secretary for a number of years before the COVID-19 pandemic, apologises "unreservedly" to the families of people who died from the illness after a report prepared by the COVID-19 Inquiry found significant flaws in the government's strategy for dealing with the pandemic. 22 July – Home Secretary Yvette Cooper confirms the UK government will resume processing asylum applications, including those from people who arrived in the UK illegally. She also tells the House of Commons the previous government's Rwanda asylum plan cost £700m, with only four people being removed to the country voluntarily. The shadow home secretary, James Cleverly, says Cooper's words are "hyperbole" and "made up numbers", adding that Labour had scrapped scheme on "ideological grounds" and that its purpose was as a deterrent. Launch of Skills England, a government body whose objective will be to reduce the need for overseas employees by improving skills training for people in England. 2024 Conservative Party leadership election: The Conservative Party's 1922 Committee sets out a timeline for the election of the next leader, with the successful candidate scheduled to be announced in early November. July 2024 Welsh Labour leadership election: Eluned Morgan becomes the first candidate to enter the leadership race.
Alpha particles emitted by polonium ionize air molecules that neutralize charges on the nearby surfaces. Some anti-static brushes contain up to 500 microcuries (20 MBq) of 210Po as a source of charged particles for neutralizing static electricity. In the US, devices with no more than 500 μCi (19 MBq) of (sealed) 210Po per unit can be bought in any amount under a "general license", which means that a buyer need not be registered by any authorities. Polonium needs to be replaced in these devices nearly every year because of its short half-life; it is also highly radioactive and therefore has been mostly replaced by less dangerous beta particle sources. Tiny amounts of 210Po are sometimes used in the laboratory and for teaching purposes—typically of the order of 4–40 kBq (0.11–1.08 μCi), in the form of sealed sources, with the polonium deposited on a substrate or in a resin or polymer matrix—are often exempt from licensing by the NRC and similar authorities as they are not considered hazardous. Small amounts of 210Po are manufactured for sale to the public in the United States as "needle sources" for laboratory experimentation, and they are retailed by scientific supply companies. The polonium is a layer of plating which in turn is plated with a material such as gold, which allows the alpha radiation (used in experiments such as cloud chambers) to pass while preventing the polonium from being released and presenting a toxic hazard. Polonium spark plugs were marketed by Firestone from 1940 to 1953.
== Perspectives == Synthetic biology is a field whose scope is expanding in terms of systems integration, engineered organisms, and practical findings. Engineers view biology as technology (in other words, a given system includes biotechnology or its biological engineering). Synthetic biology includes the broad redefinition and expansion of biotechnology, with the ultimate goal of being able to design and build engineered live biological systems that process information, manipulate chemicals, fabricate materials and structures, produce energy, provide food, and maintain and enhance human health, as well as advance fundamental knowledge of biological systems (see Biomedical engineering) and our environment. Researchers and companies working in synthetic biology are using nature's power to solve issues in agriculture, manufacturing, and medicine. Due to more powerful genetic engineering capabilities and decreased DNA synthesis and sequencing costs, the field of synthetic biology is rapidly growing. In 2016, more than 350 companies across 40 countries were actively engaged in synthetic biology applications; all these companies had an estimated net worth of $3.9 billion in the global market. Synthetic biology currently has no generally accepted definition. Here are a few examples: It is the science of genetic and physical engineering to produce new (and, therefore, synthetic) life forms.
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.